<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04487275</url>
  </required_header>
  <id_info>
    <org_study_id>23-299</org_study_id>
    <nct_id>NCT04487275</nct_id>
  </id_info>
  <brief_title>MLC901 for Moderate to Severe Traumatic Brain Injury (Specified Drug Code)</brief_title>
  <acronym>MLC901</acronym>
  <official_title>MLC901 for Moderate to Severe Traumatic Brain Injury: Pilot, Randomized, Double-Masked, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ali Amini Harandi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with a diagnosis of moderate to severe traumatic brain injury (TBI) will be
      enrolled. Subjects will be randomly assigned to receive either MLC901 (Specified Drug Code)
      or placebo capsules three times per day over 6 months. Evaluation of patients will be carried
      out at baseline as well as at 3-month and 6-month follow-up visits. Modified Rankin Scale
      (mRS) and Glasgow outcome scale (GOS) will be used to examine patients. Efficacy will be
      evaluated by comparing these two scores between the 2 groups at follow-up visits.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>functional outcome 1</measure>
    <time_frame>at baseline</time_frame>
    <description>functional outcome scales of GOS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>functional outcome 2</measure>
    <time_frame>at 3rd month post-injury</time_frame>
    <description>functional outcome scales of GOS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>functional outcome 3</measure>
    <time_frame>at 6th month post-injury</time_frame>
    <description>functional outcome scales of GOS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>functional outcome 4</measure>
    <time_frame>at baseline</time_frame>
    <description>functional outcome scales of MRS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>functional outcome 5</measure>
    <time_frame>at 3rd month post-injury</time_frame>
    <description>functional outcome scales of MRS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>functional outcome 6</measure>
    <time_frame>at 6th month post-injury</time_frame>
    <description>functional outcome scales of MRS</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MLC901 capsules three times per day over 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules three times per day over 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLC901 or Placebo</intervention_name>
    <description>groups randomly assigned to receive either MLC901 or placebo capsules three times per day over 6 months</description>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 15 and 65

          -  non-penetrating moderate (Glasgow Coma Scale score [GCS] 9-12) or severe (GCS 3-8)
             traumatic brain

          -  injury less than 24 hrs from traumatic injury

          -  anticipated intensive care unit length of stay at least 48 hrs

        Exclusion Criteria:

          -  GCS = 3 and fixed dilated pupils or penetrating injury

          -  coexisting injury or medical conditions which could adversely affect our study outcome
             measures

          -  dependence for everyday activities before the injury

          -  pregnancy or breastfeeding

          -  known allergy to any of MLC901 components
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ali Amini Harandi, MD</last_name>
    <phone>+989126026214</phone>
    <email>amini_alli@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brain Mapping Research Center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Amini Harandi, MD</last_name>
      <phone>+989126026214</phone>
      <email>amini_alli@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 17, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University</investigator_affiliation>
    <investigator_full_name>Ali Amini Harandi</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

